Search
Formaldehyde
go.drugbank.com/drugs/DB03843ApprovedVet approvedIn solution, it has a wide range of uses: in the manufacture of resins and textiles, as a disinfectant, and as a laboratory fixative or preservative. … Formaldehyde solution (formalin) is considered a hazardous compound, and its vapor toxic. (From Reynolds, Martindale The Extra Pharmacopoeia, 30th ed, p717)
Categories: Compounds used in a research, industrial, or household settingZilganersen
go.drugbank.com/drugs/DB18161ApprovedInvestigational[L64096] Alexander disease is caused by variants in the *GFAP* gene that lead to overproduction and toxic accumulation of GFAP in astrocytes, and dysfunction in astrocytes can over time damage neurons … [L64096] The FDA approved zilganersen on September 3, 2026 for the treatment of Alexander disease in pediatric and adult patients, making it the first and only disease-modifying treatment for the condition
Segesterone acetate
go.drugbank.com/drugs/DB14583ApprovedIn clinical trials, Annovera™ achieved a 97.3% success in pregnancy prevention [L4246]. Annovera™ is administered as a vaginal ring that is in place for 21 days and removed for 7 days each cycle. … It is commonly sold under the brand names Nestorone and Elcometrine and serves as an active component in hormonal contraceptives.
Mycophenolic acid
go.drugbank.com/drugs/DB01024ApprovedInvestigationalMycophenolic acid is used in immunosuppressive regimens as part of a triple therapy that includes a calcineurin inhibitor (ciclosporin or tacrolimus) and prednisolone. … [A249180,A249185] Mycophenolic acid is available as enteric-coated tablets of delayed-release, in an effort to improve upper gastrointestinal adverse events by delaying mycophenolic acid release until
Lenalidomide
go.drugbank.com/drugs/DB00480ApprovedInvestigationalzone lymphoma in selected patients. … [L16028] Due to severe teratogenicity, pregnancy must be excluded before the start of treatment and patients must enroll in the lenalidomide Risk Evaluation and Mitigation Strategy (REMS) program to ensure
Plozasiran
go.drugbank.com/drugs/DB18997ApprovedInvestigational[L45864] Plozasiran was first approved by the FDA on November 18th, 2025, to reduce triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS).[L54603] … Plozasiran contains a covalently linked ligand containing three N-acetylgalactosamine (GalNAc) residues to facilitate delivery to hepatocytes where it works to reduce triglyceride levels.
Riociguat
go.drugbank.com/drugs/DB08931ApprovedInvestigationalRiociguat is a soluble guanylate cyclase (sGC) agonist approved in the USA, Europe and several other regions for patients with group I PAH (pulmonary arterial hypertension) in WHO FC II or III; and for … the treatment of patients with inoperable CTEPH (chronic thromboembolic pulmonary hypertension), or persistent/recurrent PH (pulmonary hypertension) after pulmonary endarterectomy in WHO FC II or III.
Synonyms: Methyl N-[4,6-Diamino-2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-pyrimidinyl]-N-methyl-carbaminateHydroxyethyl ethylcellulose
go.drugbank.com/drugs/DB14139ApprovedHydroxyethyl ethylcellulose modulates bacterial binding to salivary pellicle; moderately effective in preventing plaque formation.
Categories: Compounds used in a research, industrial, or household settingSorafenib
go.drugbank.com/drugs/DB00398ApprovedInvestigationalIt targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. … [A255852] First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular carcinoma, sorafenib is also indicated to treat renal carcinoma and differentiated thyroid carcinoma
Synonyms: N-(4-Chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea, 4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-2-pyridinecarboxamideXanomeline
go.drugbank.com/drugs/DB15357ApprovedInvestigational[A264509] Advances in pre-clinical research and findings in clinical trials have led to a resurgence of interest in the cognition-enhancing potential of muscarinic agonists in schizophrenia, as it was … discovered that M1 and M4 muscarinic acetylcholine receptors are highly expressed in brain regions that are implicated in cognition.